Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg/50 mcg per spr...
FDA Drug Recall #D-0424-2019 — Class II — February 1, 2019
Recall Summary
| Recall Number | D-0424-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 1, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mylan Pharmaceuticals Inc. |
| Location | Morgantown, WV |
| Product Type | Drugs |
| Quantity | 10,390 bottles |
Product Description
Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg/50 mcg per spray, 120 Metered Sprays, 23 g net fill weight bottle, Rx Only, Manufactured by: Cipla Ltd., Goa, India, M.L. No. 546; For: Meda Pharmaceuticals Inc., Somerset, New Jersey 08873-4120, NDC 0037-0245-23.
Reason for Recall
Defective Container: Potential for broken glass in the neck area of the glass bottles.
Distribution Pattern
Nationwide in the USA.
Lot / Code Information
Lot: GA70535, Exp. April 2019
Other Recalls from Mylan Pharmaceuticals Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0049-2021 | Class III | Candesartan Cilexetil and Hydrochlorothiazide T... | Oct 2, 2020 |
| D-1057-2020 | Class III | Tacrolimus Capsules, USP 5mg, 100-count bottle,... | Mar 23, 2020 |
| D-1031-2020 | Class II | Sotalol HCL Tablets, USP (AF) 80 mg, 100 count ... | Mar 9, 2020 |
| D-0791-2020 | Class II | Nizatidine Capsules, USP 150 mg, Rx Only, Mylan... | Jan 7, 2020 |
| D-0792-2020 | Class II | Nizatidine Capsules, USP 300 mg, Rx Only, Mylan... | Jan 7, 2020 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.